Our Company - 元心科技Biotyx

Our Company

Dr. Deyuan (David)
Zhang

Researcher, Chairman and General Manager of Biotyx Medical.

 15 years of research experience in new materials and surface strengthening technology in the research institute. In 2006, he joined LifeTech (01302.HK) as Chief Technology Officer and President until he founded Biotyx in 2019.

 Won the second prize of the National Technological Invention Award in 2014, the China Patent Gold Award in 2021, and the second prize of the National Technological Invention Award again in 2023.

 70+ invention patents authorized worldwide.

 Published 10+ SCI papers in professional journals with IF>10

 As a postdoctoral supervisor, trained 10+ postdoctoral fellows.

1716013973176f85ad9955f878cdc3b757f379f1ea4de

Founder

Biotyx Medical (Shenzhen) Co., Ltd. was founded in 2019 as a subsidiary from LifeTech Scientific Corporation (01302.HK), specializing in the research and development of iron-based bioresorbable materials and devices. Biotyx Medical is the only company in the world that develops iron-based bioresorbable vascular stents. Clinical implants have been carried out in the United States, Europe, Southeast Asia and China; three products have passed the special approval procedure for innovative medical devices of the National Medical Products Administration (NMPA) and entered the "green channel". Sales licenses in the United States and Malaysia in 2021, and the CE certificate in 2023. Adhering to the mission of providing safe and innovative cardiovascular medical devices to doctors and patients around the world, Biotyx is committed to becoming a global leader in the cardiovascular field.

About Us

Why choose Biotyx?

Dedicated to
Providing doctors with safer and more effective treatment options

IBS is the only iron-based drug-eluting scaffold that can compete with traditional drug-eluting stents. It is a real BRS like DES. We believe that the future iron scaffold will definitely provide doctors with safer and more effective treatment options, bring different blood to the cardiovascular device industry, and make BRS the new mainstream of coronary intervention.